Prof of Med, Hepatologist @Methodisthosp. Researcher, Dir Houston Research Institute. Father to 2 girls. AE @AGA_CGH
Houston, TX
Joined November 2016
- Tweets2.2K
- Following2K
- Followers5.8K
- Likes4.9K
Mazen Noureddin, MD, MHSc retweeted
Could MASH be treatable earlier than we thought? New IMPACT trial findings offer promising insights for clinicians. Dr. @NoureddinMD explores what this could mean for earlier intervention and the future of MASH care. spr.ly/6017BHK6u5
Mazen Noureddin, MD, MHSc retweeted
What’s next in MASH care? Dr. @NoureddinMD explores how combination therapies could optimize treatment outcomes and shape the future of liver disease management. Discover the latest insights for clinicians: spr.ly/6011BHJh29
Mazen Noureddin, MD, MHSc retweeted
It is of great interest to evaluate if PNPLA3 G-allele modifies response to MASH therapies. In our @HEP_Journal article, histological response to effruxifermin (FGF21 agonist) is PNPLA3 genotype agnostic. Await sema, tirza, and resmetirom data.
Mazen Noureddin, MD, MHSc retweeted
We are so proud of you and know that you are destined for great things at @Columbia and @nyphospital. Looking forward to future collaboration and seeing your achievements! – at Manhattan, NY
Had the opportunity to present Grand Rounds on the evolving role of advanced endoscopy in GI oncology — from ESD to interventional EUS and how these techniques are reshaping management and patient care.
Grateful to the incredible advanced endoscopy mentors @WCM_GI, @drbobbybrown , and my amazing program director @ReemSharaiha for the mentorship, guidance, and support.
Thanks as well to our general GI fellows and staff who make this work possible.
Mazen Noureddin, MD, MHSc retweeted
Not all ALD risks are biological. Our recent work shows social deprivation increases acute complications (cardiovascular events, infections, alcohol-associated hepatitis) but not long-term liver progression.
Social determinants matter.
@PojsakornDan @NoureddinMD @KarnJUVE
📢 New Publication Alert: "Association of Documented Social Deprivation with Cardiovascular and Liver Outcomes in #Alcohol‑Associated #Liver Disease"
📌 Social vulnerability appears to heighten acute complications in ALD. @l_suthat
doi.org/10.1016/j.alcohol.20…
Mazen Noureddin, MD, MHSc retweeted
We closed #SLDSummit 2026 with a forward looking Plenary session dedicated to scanning the horizon of SLD research and care.
The discussion explored whether genetics can meaningfully guide future treatment strategies, questioning the feasibility and desirability of pan SLD drug development, and reflecting on the core skills required for the next generation of SLD specialists.
@SagiZelber @marurinella @NoureddinMD @tom_marjot
Mazen Noureddin, MD, MHSc retweeted
GUILD Maui 2026 is off to a great start! @GuildConference @UmaMahadevanIBD
Thank you @UmaMahadevanIBD and @norahterrault for the invite to be part of the great @GuildConference ! Great audience, content and location. And I got to present in a Hawaiian shirt 👕 Well done 🙌🏽. #GItwitter #livertwitter @EdwardLoftus2 @AGA_Gastro @AASLDtweets – at Santa Maria, CA
Mazen Noureddin, MD, MHSc retweeted
Prof. Mazen Noureddin presents:
“Selecting therapy in MASH: matching drugs to phenotypes.”
Highlighting a practical, phenotype-driven framework tailoring treatment to metabolic profile, fibrosis risk, and comorbidities.
#BestofTLM #SASLT #AASLD #MASH
Congrats to Madrigal Pharmaceuticals
The MASH field keeps getting exciting with all these aquistions and positive studies!
Great for our patients ! A lot of work and trials to do! #livertwitter
linkprotect.cudasvc.com/url?…
Mazen Noureddin, MD, MHSc retweeted
Review Article
MASH clinical trials and drugs pipeline: An impending tsunami
Noureddin
#LiverX
shorturl.at/oir5U
Mazen Noureddin, MD, MHSc retweeted
Still time to register for this webinar. Join us to for a practical discussion of recently approved medications in #MASH
#MASLD #Resmetirom #Rezdiffra #Semaglutide #Wegovy
📣 Join us in two weeks!
Don’t miss “Resmetirom and Semaglutide for MASH in 2025: Updated Recommendations from AASLD Guidance” — a live webinar discussing the latest updates in MASLD/MASH management, including current and emerging therapies.
📅 Tuesday, December 16, 2025
🕛 12:00 noon EST
🎙 Moderator & Panelists: Robert Fontana, MD, FAASLD, Alina Allen, MD, Jessica Bartholomew, NP, Yaron Rotman, MD, MSc, FAASLD, Meena Bensal, MD, FAASLD
💡 Earn AMA PRA Category 1 Credit™
Register today: aasld.org/resmetirom-and-sem…
Mazen Noureddin, MD, MHSc retweeted
A very Successful 2nd #HoustonCholangiocarcinomaSymposium with the @CCF, spotlighting #patientadvocacy, #research #Collaboration! Grateful to all the speakers, moderators and the patients!
@staclinds @JavleMilind @MaenAbdelrahim @melinda_bachini @RikiGravesMHA @odisio
Mazen Noureddin, MD, MHSc retweeted
@NoureddinMD chairing the the first session in our Summit....lead the discussion on 🔥 topics of hematology...AI and others!
Mazen Noureddin, MD, MHSc retweeted
What about non-invasive tests (NITs) in the hepatology community? 🤔 How can we asses liver disease without doing a liver biopsy?
📊 Data supporting the role of NITs is emerging at fast pace
🧪 While liver biopsy is still required in Phase III trials, things are evolving
🎤 Multiple sessions on this topic at #TLM
@DebbieShawcros1 @saulkarpen @allisonkwong @NoureddinMD @EASLnews @AASLDtweets @AASLDPresident
#EASLStudio #LiverX
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study - @TheLancet #livertwitter – at Hunters Creek Village, TX
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study - The Lancet thelancet.com/journals/lance…
A great week started from visting the LDB @NIH as
a VP and hanging out w friends. Then to NY running into my friend Dr. Elias Zerhouni (Former NIH director) after our meetings at the UN🇺🇳 and getting my signed copy of his new book “Disease Knows No Politics @livertwitter – at Alabama, USA
Mazen Noureddin, MD, MHSc retweeted
Join the Institute on Sept. 3 at noon for a research webinar by our director of alcohol sciences, @juanpabloarab, on "Alcohol-associated Liver Disease: From Bench to Public Health.” Register for the seminar at: bit.ly/44Vckth
Mazen Noureddin, MD, MHSc retweeted
❗ Data from the ESSENCE trial led the #FDA to approve #Wegovy for certain adults with noncirrhotic #MASH.
✍️ @NoureddinMD of @MethodistHosp said the approval is a “welcome step that broadens options” for such patients.
bit.ly/4m0a6y5
New in the @TheLancet :Arguably the highest fibrosis improvement in #MASH trials to date #livertwitter @ebtapper @schattenbergJ @AlkhouriNaim @akerotx @scottisaacsmd @NoureddinNabil @ArunJSanyalVCU
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet thelancet.com/journals/lance… – at Piney Point Village, TX